An American investment company has made its first move into the European cannabis space.

On Monday (September 23), New York-based Altitude Investment Management (AIM) announced a US$5.5 million investment into Switzerland-based cannabidiol (CBD) company KannaSwiss.


The privately held investment firm has described its new investment as “the leading supplier of top-tier CBD isolate products in Europe.”

Roderick Stephan, co-founder of Altitude, told the Investing News Network (INN) that this move will help solidify the company’s stake in Europe as the market continues to develop over time.

“On the one hand, people think it’s going to evolve much more quickly because of this past experience in North America. On the other hand, the different countries and different opinions about medical cannabis, as well as about CBD wellness, make it a much different evolutionary path,” said Stephan.

He added, though, that Europe poses an “attractive risk/reward” factor because investors are still able to get an early position compared to the evolving markets in the US and Canada.

Stephan told INN in an email that AIM is attempting to gain the most out of its early mover status in the emerging European cannabis marketplace.

According to Stephan, the European market lags behind North America’s by three to four years.

Stephan cited KannaSwiss’ prominence in CBD extraction and its operational success as the main factors for AIM’s investment in the manufacturer.

Funds from the investment will be used by KannaSwiss to scale up its extraction operations for CBD isolate and distillate, and help it develop marketing for its line of branded CBD extracts, supplements and edible products.

The investment will also help KannaSwiss attempt to attain the ISO 9000 quality standard as well as good manufacturing practices certification.

The ISO 9000 quality management system, established by the International Organization for Standardization, is a set of international quality standards that helps companies maintain an effective quality assurance system.

KannaSwiss CEO Boris Blatnik said in a statement that the company is focusing on maintaining its reputation as a trusted CBD brand.

“Swiss manufacturing holds itself to the highest standards, so I am confident that my team’s dedication to quality and innovation will produce a leading line of products on the European market,” he added.

One of the benefits of this transaction for AIM is the chance to operate in Switzerland, which has a higher tetrahydrocannabinol (THC) allowance for cannabis plants than other countries on the continent, according to Stephan.

In Switzerland, products made from cannabis plants that contain up to 1 percent THC can be bought and sold legally. Other countries in the EU have THC content capped at 0.3 percent.

Legislation on cannabis use is still fragmented across Europe, but analysts have been favorable about the continued growth of Europe’s cannabis space.

A report from Prohibition Partners projects Europe’s cannabis industry could be worth 123 billion euros by 2028. Estimates from Brightfield Group say the cannabis space in Europe was worth US$318 million in 2018 and could grow over 400 percent through 2023.

AIM plans to focus its efforts on private cannabis companies in Europe’s supply chain. Stephan said the firm plans on expanding its portfolio in Europe into 2020 with more investments, noting that the firm is also interested in exploring investment opportunities in Israel’s burgeoning cannabis research space.

Don’t forget to follow us @INN_Cannabis for real-time news updates!

Securities Disclosure: I, Danielle Edwards, hold no direct investment interest in any company mentioned in this article.

Editorial Disclosure: The Investing News Network does not guarantee the accuracy or thoroughness of the information reported in the interviews it conducts. The opinions expressed in these interviews do not reflect the opinions of the Investing News Network and do not constitute investment advice. All readers are encouraged to perform their own due diligence.

Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, is pleased to announce the appointment of Mr. Al Reese, Jr., to its Board of Directors

Mr. Reese has over 40 years experience in public and private businesses including as CFO of a formerly Nasdaq-listed energy company where he arranged finance transactions totaling over $10 billion dollars during his 20-year tenure. Mr. Reese was a Director and Chairman of the Audit Committee of a community bank in Texas for ten years until such time as it was acquired by a larger banking group in 2018.

Keep reading... Show less

Mexico looks to be closer than ever to cannabis reform, with the country releasing its regulation plans to make the drug legal in medical settings.

Meanwhile, despite the financial hardships seen recently in the Canadian cannabis market, CEOs in the country are still receiving top dollar, as per a new study.

Keep reading... Show less

Not for Distribution to United States Newswire Services or for Dissemination in the United States

Cresco Labs (CSE:CL) (OTCQX:CRLBF) (“Cresco” or the “Company”), one of the largest vertically integrated multistate cannabis operators in the United States, announced today the pricing of its previously announced best efforts overnight marketed offering (the “Offering”) of subordinate voting shares (the “Offered Securities”) of the Company at a price of C$16.00 per share for a total gross proceeds of approximately US$125 Million. The issue price represents a 3.3% discount to the last close of the Company’s subordinate voting shares traded on the Canadian Securities Exchange as of January 14, 2021. 100% of the Offering is expected to be purchased by a total of seven new and existing institutional investors, including current shareholder, Wasatch Global Investors.

Keep reading... Show less

Wall Street Reporter, the trusted name in financial news since 1843, has published reports on the latest comments and insights from leaders at: Tilray, Inc. (NASDAQ: TLRY), Icanic Brands (OTC: ICNAF) (CSE: ICAN) Red Light Holland (OTC: TRUFF) (CSE: TRIP) and Aphria, Inc. (NASDAQ: APHA).

Investors are cheering new and expected legislation which is opening new market opportunities for both cannabis and psychedelics globally. Innovation in premium branding, growing technologies, manufacturing, with operational execution are key, in the drive towards profitability. Wall Street Reporter highlights the latest comments from industry thought leaders in cannabis and psychedelics:

Keep reading... Show less

Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the “Company”) today announced the closing of its previously announced underwritten public offering (the “Offering”) of 1,828,571 units, each unit consisting of one share of common stock and one warrant to purchase one share of common stock at a public offering price of $5.25 per unit (all prices in US$). The warrants have an exercise price of $6.58 per share, are immediately exercisable and will expire five years following the date of issuance. In connection with the Offering, the underwriter exercised in full its option to purchase an additional 274,285 shares of common stock and additional warrants to purchase 274,285 shares of common stock. The gross proceeds from the Offering were approximately $11.04 million, before deducting underwriting discounts and estimated offering expenses. No securities were offered or sold in Canada, including through the CSE or any other trading market in Canada

H.C. Wainwright & Co. (“Wainwright”) acted as the sole book-running manager for the Offering and is a non-related party to the Company.

Keep reading... Show less